Several Israeli and European companies use our capabilities to source mAbs (APIs) e.g. Rituximab, Nivolumab biosimilars and other biologicals for repurposing applications of these drugs into orphan indications. On the same basis, the mAb Adalimumab as biosimilar API was supplied through Bio-Lead to a Dutch company for the development of an oral route of administration instead of the current injection route.